Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma.
Roderick F J O'DayKelsey A RoelofsGuy S NegrettiGordon HayAmit K AroraIan StokerBertil E DamatoMandeep S SagooVictoria M L CohenPublished in: Eye (London, England) (2022)
Most patients treated with ruthenium plaque brachytherapy for posterior choroidal melanoma retain 6/60 vision, with almost half retaining 6/12 vision at long term follow up.